FACIT forms biotechnology company for OICR-discovered first-in-class epigenetic modifiers
TORONTO, June 23, 2016
The WDR5 protein is critical for the formation and epigenetic activities of MLL1-associated methylation complexes. Deregulation of the MLL1 complexes has been implicated in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Propellon's series of novel WDR5 epigenetic modifiers target protein-protein interactions within the WDR5/MLL1 complex and thereby disrupt pro-cancer methylation activities. This unique approach may also improve clinical outcomes in patients with solid tumours and is currently under investigation by the Company and its partners.
Propellon will continue to collaborate with the OICR Drug Discovery team and build upon their significant progress in preclinical development. During an initial transitional period, FACIT will provide interim corporate management. Should candidate drugs achieve the milestone of testing in human patients, Propellon has the potential to access the robust infrastructure for high content clinical trials in Ontario.
"OICR and FACIT share a mission to translate advancements in cancer care for the benefit of both patients and the Ontario economy," said Jeff Courtney, Chief Commercial Officer of FACIT. "With a focus on accelerating the development of these promising WDR5 inhibitor therapies, Propellon is well-positioned to attract investment and global pharma partners to Ontario, and increase the likelihood of successful translation and improved patient care."
About FACIT FACIT is an independent business trust established by OICR to accelerate breakthrough cancer innovations into viable opportunities that benefit patients, researchers, investors and Ontario's economy. For more information, please visit facit.ca or email [email protected].
About OICROICR is an innovative cancer research and development institute dedicated to prevention, early detection, diagnosis and treatment of cancer. The Institute is an independent, not-for-profit corporation, supported by the Government of Ontario. OICR and its funding partners support research programs that involve more than 1,700 investigators, clinician scientists, research staff and trainees in research institutes and in universities across the Province of Ontario as well as at its headquarters. OICR has key research program efforts underway in small molecules, biologics, stem cells, imaging, genomics, informatics and bio-computing. For more information, please visit www.oicr.on.ca.
About Propellon TherapeuticsPropellon Therapeutics is developing and commercializing novel cancer therapies targeting the WDR5 protein, essential for assembly of methyltransferase complexes and proper histone modification. The overexpression of WDR5 and resulting deregulation of epigenetic mechanisms are implicated in various cancers and correlated with poor patient survival. Established by FACIT, Propellon's WDR5 inhibitor platform arises from discoveries, research and innovations originating from OICR. For more information, please email [email protected].
SOURCE Fight Against Cancer Innovation Trust
Subscribe to our Free Newsletters!
A prosthetic heart valve is an artificial device surgically implanted into the heart to replace a ...
PUVA or photochemotherapy is used to treat several skin disorders with the help of UV light and the ...
Breathing in unclean air due to increasing air pollution could cause kidney damage with resultant ...View All